ADVERTISEMENT
Search

Pharmacy News

Study links statins with more aggressive diabetes progression

Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.

Uptake of newer diabetes products dominate trends in U.S. adults with diabetes

New research published in JAMA Network Open finds that insulin glargine and other insulin analogs are the most-used forms of insulin in the United States, alongside pen devices as a delivery method.

Walmart–Novo Nordisk insulin offers deep discounts to select few

Early last summer, Walmart announced the launch of a new private brand, cash-pay analog insulin, made by drug manufacturer Novo Nordisk. Sold under Walmart’s private ReliOn label, vials go for $72.88 each and FlexPens for $85.88 each. Walmart calculates that the products will save customers between 58% and 75% of the cash price for branded analog insulin products, which translates to savings of up to $101 per branded vial or $251 per package of branded FlexPens. But, for many who struggle with the day-to-day costs of living with diabetes, these brands may still be tough to afford. Other pharmacies or drug-maker patient assistance programs may offer more support to cash-strapped patients.

Non-Hispanic Black and Mexican-American adults diagnosed with diabetes at a younger age

New findings published in JAMA Network revealed that non-Hispanic Black and Mexican-American adults were diagnosed with diabetes at a younger age—typically 4 to 7 years earlier—than non-Hispanic whites. 

Can a diabetes medication benefit asthma patients?

GLP-1 receptor agonists may benefit patients who have asthma, suggests new research published in the American Journal of Respiratory and Critical Care Medicine.

RSS
Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT